UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Leonard maintains a Neutral rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $30 to $25.
August 13, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Dan Leonard maintains a Neutral rating on 10x Genomics (TXG) but lowers the price target from $30 to $25.
The lowered price target from $30 to $25 by UBS suggests a less optimistic outlook for 10x Genomics, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100